{"adverse_reactions":["ADVERSE REACTIONS: Adverse reactions involve the possibility of combined sodium and phosphorus intoxication from overdosage. Sodium replacement therapy should be guided primarily by the serum sodium level. Use with caution in patients with renal impairment, cirrhosis, cardiac failure or other edematous or sodium retaining states. Phosphorus intoxication results in a reduction of serum calcium, and the symptoms are those of hypocalcemic tetany. See WARNINGS ."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY: Phosphorus in the form of organic and inorganic phosphate has a variety of important biochemical functions in the body and is involved in many significant metabolic and enzyme reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium and a primary role in the renal excretion of hydrogen ion. Phosphorus is present in plasma and other extracellular fluid, in cell membranes and intracellular fluid, as well as in collagen and bone. Phosphorus in the extracellular fluid is primarily in inorganic form, and plasma levels may vary somewhat with age. The ratio of disodium phosphate and monosodium phosphate in the extracellular fluid is 4:1 (80% : 20%) at the normal pH of 7.4. This buffer ratio varies with the pH, but owing to its relatively low concentration, it contributes little to the buffering-capacity of the extracellular fluids. Phosphorus, present in large amounts in erythrocytes and other tissue cells, plays a significant intracellular role in the synthesis of high energy organic phosphates. Hypophosphatemia should be avoided during periods of total parenteral nutrition, or other lengthy periods of intravenous infusions. Serum phosphorus levels should be regularly monitored, and appropriate amounts of phosphorus should be added to the infusions to maintain normal serum phosphorus levels. Intravenous infusion of inorganic phosphorus may be accompanied by a decrease in the serum level and urinary excretion of calcium. The normal level of serum inorganic phosphorus is 3.0 to 4.5 mg/dL in adults and 4.0 to 7.0 mg/dL in children. Intravenously infused phosphorus not taken up by the tissues is excreted almost entirely in the urine. Sodium is the principal cation of extracellular fluids. The sodium ion exerts a primary role in controlling total body water and its distribution."],"contraindications":["CONTRAINDICATIONS: Sodium Phosphates Injection, USP is contraindicated in diseases where high sodium, high phosphorus or low calcium levels may be encountered."],"description":["DESCRIPTION: Sodium Phosphates Injection, USP is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic and dibasic sodium phosphate in Water for Injection. It must be diluted prior to administration. Each mL of the solution consists of two phosphate salts provided as follows: Ingredient (s) Phosphorus Sodium Monobasic Sodium Phosphate Monohydrate - 276 mg 93 mg or 92 mg or Dibasic Sodium Phosphate Anhydrous – 142 mg 3 mM 4 mEq The solution contains no bacteriostatic agent or other preservative. The solution is intended to provide phosphate ion: (PO 4 -3 ) for addition to large volume infusion fluids for intravenous use. Unused portions should be discarded."],"description_table":["
Ingredient (s) Phosphorus Sodium
Monobasic Sodium Phosphate Monohydrate - 276 mg 93 mg or 92 mg or
Dibasic Sodium Phosphate Anhydrous – 142 mg 3 mM 4 mEq
"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: Sodium Phosphates Injection, USP is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mM) of phosphorus and milliequivalents (mEq) of sodium."],"drug_interactions":["Drug Interactions Concurrent use with thiazides may cause renal damage."],"effective_time":"20170719","how_supplied":["HOW SUPPLIED: Sodium Phosphates Injection, USP 3mM Phosphorus/mL, 4 mEq Sodium/mL NDC 0517-3405-25 5 mL Single Dose Vial packed in boxes of 25 NDC 0517-3415-25 15 mL Single Dose Vial packed in boxes of 25 NDC 0517-3450-25 50 mL Single Dose Vial packed in boxes of 25 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature). These products do not contain a bacteriostatic agent or other preservatives. Any unused portion should be discarded. AMERICAN REGENT, INC. SHIRLEY, NY 11967 IN3405 Rev. 11/05"],"how_supplied_table":["
NDC 0517-3405-25 5 mL Single Dose Vial packed in boxes of 25
NDC 0517-3415-25 15 mL Single Dose Vial packed in boxes of 25
NDC 0517-3450-25 50 mL Single Dose Vial packed in boxes of 25
"],"id":"f5d228a2-e2fc-4041-a0e0-c868278af528","indications_and_usage":["INDICATIONS AND USAGE: Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions."],"openfda":{},"overdosage":["OVERDOSAGE: In the event of overdosage, discontinue infusions containing Sodium Phosphates Injection, USP immediately, and institute corrective therapy. (See WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 5 mL Container NDC 0517-3405-25 SODIUM PHOSPHATES INJECTION, USP 15 mM/5 mL Phosphorus 20 mEq/ 5 mL Sodium 5 mL SINGLE DOSE VIAL FOR IV USE AFTER DILUTION Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 PRINCIPAL DISPLAY PANEL - 5 mL Container","PRINCIPAL DISPLAY PANEL – 15 mL Container NDC 0517-3415-25 SODIUM PHOSPHATES INJECTION, USP 45 mM/15 mL Phosphorus 60 mEq/15 mL Sodium 15 mL SINGLE DOSE VIAL FOR IV USE AFTER DILUTION Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 PRINCIPAL DISPLAY PANEL – 15 mL Container","PRINCIPAL DISPLAY PANEL – 50 mL Container NDC 0517-3450-25 SODIUM PHOSPHATES INJECTION, USP 150 mM/50 mL Phosphorus 200 mEq/50 mL Sodium 50 mL SINGLE DOSE VIAL FOR IV USE AFTER DILUTION Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 PRINCIPAL DISPLAY PANEL – 50 mL Container"],"precautions":["PRECAUTIONS: Phosphorus replacement therapy with sodium phosphates should be guided primarily by the serum inorganic phosphorus levels and the limits imposed by the accompanying sodium (Na + ) ion. Frequent monitoring of serum calcium and sodium as well as renal function is recommended. Use with caution in patients with renal impairment, cirrhosis, cardiac failure or in conjunction with other edema causing medications. It should not be used with sodium retaining medications. Caution must be exercised in the administration of parenteral fluids especially those containing sodium ion, to patients receiving corticosteroids or corticotropin. Drug Interactions Concurrent use with thiazides may cause renal damage. Pregnancy : Teratogenic Effects . Pregnancy Category C. Animal reproduction studies have not been conducted with sodium phosphate. It is also not known whether sodium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium phosphate should be given to a pregnant woman only if clearly needed."],"pregnancy":["Pregnancy : Teratogenic Effects . Pregnancy Category C. Animal reproduction studies have not been conducted with sodium phosphate. It is also not known whether sodium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium phosphate should be given to a pregnant woman only if clearly needed."],"set_id":"348ecd15-59c0-4833-88ea-7acf6ac0dbef","spl_product_data_elements":["Sodium Phosphates sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE PHOSPHATE ION SODIUM PHOSPHATE, DIBASIC, ANHYDROUS PHOSPHATE ION WATER Sodium Phosphates sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE PHOSPHATE ION SODIUM PHOSPHATE, DIBASIC, ANHYDROUS PHOSPHATE ION WATER Sodium Phosphates sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE PHOSPHATE ION SODIUM PHOSPHATE, DIBASIC, ANHYDROUS PHOSPHATE ION WATER"],"spl_unclassified_section":["Rx Only CAUTION: FOR INTRAVENOUS USE ONLY MUST BE DILUTED PRIOR TO ADMINISTRATION"],"version":"5","warnings":["WARNINGS Sodium Phosphates Injection, USP must be diluted and thoroughly mixed before use. To avoid phosphorus intoxication, infuse solutions containing sodium phosphate slowly. Infusing high concentrations of phosphorus may result in a reduction of serum calcium and symptoms of hypocalcemic tetany. Calcium levels should be monitored. Solutions containing sodium ion should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particulary at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."]}